GlassScriptPhysician profile
David R Farzan
NPI 1093719924
$23,443.49
in general payments reported to CMS, 2019-2025
50 companies · $3,627 in 2025
The $3,627 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,596 · 2020: $2,292 · 2021: $4,437 · 2022: $3,220 · 2023: $3,505 · 2024: $2,767 · 2025: $3,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,879 · Education: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,879.03 |
| Education | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,826.08 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,661.51 | 2019-2025 | Farxiga, Breztri, Wainua |
| Pfizer INC. | $2,227.29 | 2019-2025 | |
| Lilly USA, LLC | $1,775.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,609.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,120.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $989.60 | 2021-2025 | |
| Amgen INC. | $936.30 | 2019-2025 | Repatha, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $929.14 | 2019-2025 | Jardiance, Spiriva Respimat, Jascayd |
| Teva Pharmaceuticals USA, INC. | $794.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $749.15 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $727.36 | 2019-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $505.89 | 2020-2021 | |
| Allergan, INC. | $491.17 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.54 | 2019-2025 | Xifaxan |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Farzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.